Onyx Scientific Limited Bolsters U.S. Team

Onyx Scientific Limited Bolsters U.S. Team

11/19/2012 12:18:41 PM

November 2012 -- CHEMISTRY CRO Onyx Scientific has strengthened its US presence with the appointment of a Chicago-based business development director.

Dan Brisard will oversee the contract manufacturing organisation's business development activities across the eastern half of the US.

An experienced commercial executive, Dan has worked across the pharmaceutical manufacturing sector for around fifteen years including seven years with Ricerca Bioscience.

A graduate in Chemistry from the University of Illinois and in Analytical Chemistry from the Illinois Institute of Technology, Dan also brings technical knowhow to his new role that will assist the company's US-based pharmaceutical and biotech clients.

Denise Bowser, commercial director at Onyx Scientific, said: "Having Dan on board is a massive boost to the company as he brings exceptional commercial experience gained in the industry along with a strong chemistry background.

"At the request of our customers, we have really looked to expand our offering over the last year to minimise the need for clients to use several suppliers on the same project.

"Dan will play a key role in communicating the breadth of our services in addition to our track record and achievements to the US market," added Denise.

With MHRA and FDA facilities in the UK and India, Onyx Scientific assists companies from medicinal chemistry and preclinical through Phase I-III, scaling-up to large scale commercial API production.

Dan Brisard, newly-appointed business development director at Onyx Scientific, said, "I have been really impressed with Onyx Scientific over the last few years and was attracted by the company's strong reputation in the contract chemistry and manufacturing marketplace.

"The team is very experienced and we have some serious capabilities when it comes to lead optimisation, process development, solid-state chemistry and GMP synthesis. I look forward to working with my new colleagues to help the company meet its commercial ambitions and increase market share in the US."

In recent months, Onyx Scientific has expanded its services to the global pharmaceutical market by striking alliances with purification and separation specialist Reach Separations and contract research and manufacturing organisation Molecular Profiles to support its end-to-end services from drug discovery through to late phase manufacturing.

Onyx Scientific's UK-based labs deal with complex chemistry to deliver early stage programs and is then able to scale-up, tech transfer and increase project efficiency using its commercial manufacturing sites in India.

For more information about Onyx Scientific – visit www.onyxipca.com and follow at www.twitter.com/onyxscientific1

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.